Salesof 700 billion won Samsung Biologics, the third-largest market cap, is due to CDMO.
Multinational pharmaceutical companies, trend for new drug development and production request to CDMO
Bio-venturesare lack of capacity, essential contract manufacturing with CDMO
Securing new drug development and high-quality drug production know-how is essential
Long-termequivalence creates high value-added, blue ocean
Attention to Quratis, Cdmogen CDMO
[A bird’s-eyeview of Quratis bio-plant located in Chungbuk, Osong]
While major domestic pharmaceutical companies are the main players in the CDMO business, small and medium-sized bio-venture companies are also drawing attention. Examples include Quratis, a developer of tuberculosis vaccines for teenagers and adults, and Cdmogen, a company specializing in gene and cell therapies. Quratis is a case in which the company started the CDMO business by utilizing its know-how in developing vaccines for adults and production facilities already built. "In the case of bio ventures that lack a production base, there is a high demand for CDMO businesses," said Cho Kwan-goo, CEO of Quratis. "We jump into this project to maximize the utilization of production facilities for startups that are difficult to use global CDMO companies and small and medium-sized companies that lack financial power while at the same time utilizing their own product development skills.".
